These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 16293867

  • 1. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
    Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ.
    J Clin Oncol; 2005 Nov 20; 23(33):8371-9. PubMed ID: 16293867
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 20; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 3. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 4. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 16; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 5. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 16; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 6. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 16; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH.
    J Clin Oncol; 1995 Jul 16; 13(7):1615-22. PubMed ID: 7602350
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.
    Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S, Hardy C, Thatcher N.
    Semin Oncol; 1995 Jun 16; 22(3 Suppl 7):32-41. PubMed ID: 7610397
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.
    J Natl Cancer Inst; 2005 May 04; 97(9):666-74. PubMed ID: 15870437
    [Abstract] [Full Text] [Related]

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 04; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 04; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 12. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
    Iwasaki Y, Nagata K, Nakanishi M, Natuhara A, Kubota Y, Ueda M, Arimoto T, Hara H.
    Chest; 2005 Oct 04; 128(4):2268-73. PubMed ID: 16236883
    [Abstract] [Full Text] [Related]

  • 13. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M.
    J Clin Oncol; 1999 Nov 04; 17(11):3531-9. PubMed ID: 10550151
    [Abstract] [Full Text] [Related]

  • 14. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R.
    Ann Oncol; 1997 Jan 04; 8(1):49-56. PubMed ID: 9093707
    [Abstract] [Full Text] [Related]

  • 15. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H, Heim M, Hruska D, Mende S, Becker H.
    J Clin Oncol; 1991 Apr 04; 9(4):614-24. PubMed ID: 1648598
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
    Lee HS, Lee YG, Koo DH, Oh S, Nam H, Song JU, Lim SY, Lim SY, Lee SS.
    Cancer Chemother Pharmacol; 2015 Nov 15; 76(5):933-7. PubMed ID: 26374553
    [Abstract] [Full Text] [Related]

  • 18. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
    Bleehen NM, Girling DJ, Machin D, Stephens RJ.
    Br J Cancer; 1993 Dec 15; 68(6):1150-6. PubMed ID: 8260367
    [Abstract] [Full Text] [Related]

  • 19. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC, McCrystal MR, Christmas TI.
    N Z Med J; 1998 Nov 27; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [Abstract] [Full Text] [Related]

  • 20. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 27; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.